Home
About
Overview
Sharing Data
ORCID
Help
History (6)
Bone health history in breast cancer patients on aromatase inhibitors.
Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Nutritional factors in ovarian cancer survival.
Re: "The impact of dietary measurement error on planning sample size required in a cohort study".
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
See All 6 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
View in:
PubMed
subject areas
Age Factors
Aged
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Bone Density
Breast Neoplasms
California
Chemotherapy, Adjuvant
Diphosphonates
Female
Follow-Up Studies
Humans
Mastectomy
Middle Aged
Osteoporosis
Postmenopause
Prevalence
Prospective Studies
Treatment Outcome
authors with profiles
Joan C. Lo, MD
Marilyn L. Kwan, PhD
Charles P. Quesenberry, PhD
Lawrence H. Kushi, ScD